Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Britannia Life SciencesFRA:L020 35 EV-to-EBITDA is -0.39 as of Sep. 01, 2026. GuruFocus rates FRA:L020 with a GF Score™ of 35/100. The stock has 5 warning signs investors should review. Among 402 Biotechnology companies, Britannia Life Sciences ranks better than 99.25% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Britannia Life Sciences's enterprise value is €-3.34 Mil.
Britannia Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €8.48 Mil. Therefore, Britannia Life Sciences's EV-to-EBITDA for today is -0.39.
The historical rank and industry rank for Britannia Life Sciences's EV-to-EBITDA or its related term are showing as below:
FRA:L020'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.11 Med: -1.69 Max: 19.25
Current: -0.39
During the past 6 years, the highest EV-to-EBITDA of Britannia Life Sciences was 19.25. The lowest was -7.11. And the median was -1.69.
FRA:L020's EV-to-EBITDA is ranked better than 99.25% of 402
companies
in the Biotechnology industry
Industry Median: 13.8
vs FRA:L020: -0.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Britannia Life Sciences (FRA:L020) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Britannia Life Sciences's PE Ratio (TTM) for today is calculated as:
Britannia Life Sciences's share price for today is €0.0285.
Britannia Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.069.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:L020 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Britannia Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Britannia Life Sciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Britannia Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Britannia Life Sciences's EV-to-EBITDA falls into.
Britannia Life Sciences's current Enterprise Value is €-3.34 Mil.
Britannia Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Britannia Life Sciences (FRA:L020) has a EV-to-EBITDA of -0.39 as of Sep. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Britannia Life Sciences. According to the industry distribution chart, Britannia Life Sciences ranks #3 out of 402 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Britannia Life Sciences' EV-to-EBITDA too high?
Britannia Life Sciences' current EV-to-EBITDA is -0.39. Based on the distribution chart, Britannia Life Sciences ranks #3 out of 402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Britannia Life Sciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Britannia Life Sciences' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Britannia Life Sciences ranks #3 out of 402 companies for EV-to-EBITDA. This places Britannia Life Sciences in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Britannia Life Sciences. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Britannia Life Sciences's current EV-to-EBITDA is -0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Britannia Life Sciences stock overvalued right now?
Britannia Life Sciences (FRA:L020) has a current EV-to-EBITDA of -0.39. The current EV-to-EBITDA is -0.39. Britannia Life Sciences' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Britannia Life Sciences (FRA:L020), the current EV-to-EBITDA is -0.39 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Britannia Life Sciences Inc provides product testing, safety assessment, and manufacturing services to the cosmetic and consumer packaged goods industries in the United Kingdom and globally.
35GF Score
Get the complete analysis for FRA:L020
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L020 has been successfully added to your 
